REG - AstraZeneca PLC - AZN harmonises listing structure

AstraZenecaAnnouncement

29/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250929:nRSc1786Ba&default-theme=true

RNS Number : 1786B  AstraZeneca PLC  29 September 2025

 

 

29 September 2025

 

AstraZeneca to harmonise its listing structure across the London Stock
Exchange, Nasdaq Stockholm and New York Stock Exchange

 

Harmonisation of listing structure requires a direct listing of AstraZeneca
shares on the NYSE in place of existing US ADRs

 

AstraZeneca continues to be listed, headquartered and tax resident in the UK

 

AstraZeneca plans to harmonise its share listing structure to deliver a global
listing for global investors in a global company. The Board of AstraZeneca is
recommending to shareholders a Harmonised Listing Structure for the Company's
ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO)
and the New York Stock Exchange (NYSE).

This requires upgrading AstraZeneca's existing US equity listing by way of a
direct listing of AstraZeneca ordinary shares on the NYSE, replacing the
existing US listing of AstraZeneca ADRs on Nasdaq. Following implementation of
the Harmonised Listing Structure, shareholders will be able to trade their
interests in AstraZeneca ordinary shares across the LSE, STO and NYSE.

Michel Demaré, Chair, AstraZeneca said: "Today we set out our proposed
harmonised listing structure which will support our long-term strategy for
sustainable growth, while remaining headquartered in the UK and listed in
London, Stockholm and New York. Enabling a global listing structure will allow
us to reach a broader mix of global investors and will make it even more
attractive for all our shareholders to have the opportunity to participate in
AstraZeneca's exciting future."

AstraZeneca's scientific and commercial achievements have been underpinned by
its continuous adaptation to a rapidly changing and dynamic industry
environment, including diversifying its access paths to capital markets. The
US has the world's largest and most liquid public markets by capitalisation,
and the largest pool of innovative biopharma companies and investors. The
Board is determined to ensure that the AstraZeneca Group has the flexibility
to access the broadest available pool of capital, including in the US, which
today's announcement will make possible.

The Harmonised Listing Structure will not change AstraZeneca's current status
as a UK listed, headquartered and tax resident company which will continue to
be included in the FTSE 100 index and the OMX Stockholm 30 index. The Company
will remain bound by applicable UK governance principles and standards
(including the Companies Act 2006 and the UK Corporate Governance Code)
following the implementation of the Harmonised Listing Structure.

A Circular incorporating a notice of General Meeting and containing further
details regarding the proposed Harmonised Listing Structure has been published
on the Company's website at
https://www.astrazeneca.com/investor-relations/shareholder-information.html#2025-0
(https://www.astrazeneca.com/investor-relations/shareholder-information.html#2025-0)
and will shortly be made available to shareholders and persons with
information rights ahead of the general meeting of the Company to be held on
Monday 3 November 2025 at  2:30 p.m. (GMT). Full details and joining
instructions are set out in the Circular.

Copies of the following documents have been submitted to the National Storage
Mechanism and will shortly be available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) :

·    Circular and notice of General Meeting;

·    Form of Proxy for the General Meeting;

·    the Company's existing articles of association, marked up to show the
proposed changes; and

·    the Company's proposed new articles of association.

 

Cautionary statement regarding forward-looking statements

 

This document contains certain forward-looking statements, including, among
other things, statements about the expected impact of the Harmonised Listing
Structure on AstraZeneca and shareholders of AstraZeneca. Although the
AstraZeneca Group believes its expectations are based on reasonable
assumptions, any forward-looking statements, by their very nature, involve
risks and uncertainties and may be influenced by factors that could cause
actual outcomes and results to be materially different from those predicted.
The forward-looking statements reflect knowledge and information available at
the date of preparation of this document and the AstraZeneca Group undertakes
no obligation to update these forward-looking statements. The AstraZeneca
Group identifies the forward-looking statements by using the words
'anticipates', 'believes', 'expects', 'intends', 'will' and similar
expressions in such statements.

 

Important factors that could cause actual results to differ materially from
those contained in forward-looking statements, certain of which are beyond the
AstraZeneca Group's control, include, among other things: the risk of failure
or delay in delivery of pipeline or launch of new medicines; the risk of
failure to meet regulatory or ethical requirements for medicine development or
approval; the risk of failures or delays in the quality or execution of the
AstraZeneca Group's commercial strategies; the risk of pricing, affordability,
access and competitive pressures; the risk of failure to maintain supply of
compliant, quality medicines; the risk of illegal trade in the AstraZeneca
Group's medicines; the impact of reliance on third-party goods and services;
the risk of failure in information technology or cybersecurity; the risk of
failure of critical processes; the risk of failure to collect and manage data
and artificial intelligence in line with legal and regulatory requirements and
strategic objectives; the risk of failure to attract, develop, engage and
retain a diverse, talented and capable workforce; the risk of failure to meet
our sustainability targets, regulatory requirements and stakeholder
expectations with respect to the environment; the risk of the safety and
efficacy of marketed medicines being questioned; the risk of adverse outcome
of litigation and/or governmental investigations; intellectual  property
risks related to the AstraZeneca Group's products; the risk of failure to
achieve strategic plans or meet targets or expectations; the risk of
geopolitical and/or macroeconomic volatility disrupting the operation of our
global business; the risk of failure in internal control, financial reporting
or the occurrence of fraud; and the risk of unexpected deterioration in the
AstraZeneca Group's financial position.

 

Notes

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)
. The contents of AstraZeneca's website do not form part of this document and
no one should rely on such websites or the contents thereof in reading this
document.

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDZGZLKLMGKZG